Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback